Literature DB >> 6890309

Coronary risk factors and plasma sex hormones.

J Lindholm, P Winkel, U Brodthagen, F Gyntelberg.   

Abstract

Recent studies have reported higher plasma estradiol levels in male survivors of acute myocardial infarction. This finding has raised the possibility that hyperestrogenemia may consitiute a separate coronary risk factor. In 443 men, aged 30, 40, 50, and 60, we assessed the relationship between plasma levels of estradiol, testosterone, and testosterone-binding globulin and coronary risk factors: fasting plasma concentrations of triglyceride, cholesterol, and high-density lipoprotein, blood pressure, and smoking and leisure-time physical activity patterns. Plasma estradiol concentrations were found to correlate significantly with body weight. After adjustment for this association, we found that the mean plasma estradiol concentration still was significantly higher in smokers than in nonsmokers. No other correlation could be estabilished between plasma hormone levels and coronary risk factors. The relative hyperestrogenemia reported in men with previous myocardial infarction may be due to an effect of smoking but may also reflect the relationship between body weight and plasma estradiol levels. Future studies should consider the demonstrated association between plasma estrogen levels and smoking.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6890309     DOI: 10.1016/0002-9343(82)90405-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Testosterone and cigarette smoking in early adolescence.

Authors:  K E Bauman; V A Foshee; G G Koch; N J Haley; M I Downton
Journal:  J Behav Med       Date:  1989-10

2.  The effect of ketoconazole and transdermal estradiol on serum sex steroid hormones levels.

Authors:  G S Hughes; S F Francom; C R Spillers; T V Ringer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Sex steroids and heart rate variability in patients after myocardial infarction.

Authors:  Jerzy Krzysztof Wranicz; Marcin Rosiak; Iwona Cygankiewicz; Piotr Kula; Krzysztof Kula; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-04       Impact factor: 1.468

4.  Body composition, not body weight, is related to cardiovascular disease risk factors and sex hormone levels in men.

Authors:  K R Segal; A Dunaif; B Gutin; J Albu; A Nyman; F X Pi-Sunyer
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

5.  The low plasma testosterone levels of young Indian infarct survivors are not due to a primary testicular defect.

Authors:  M Sewdarsen; I Jialal; R K Naidu
Journal:  Postgrad Med J       Date:  1988-04       Impact factor: 2.401

6.  Cross-sectional association between physical activity and serum testosterone levels in US men: results from NHANES 1999-2004.

Authors:  J A Steeves; E C Fitzhugh; G Bradwin; K A McGlynn; E A Platz; C E Joshu
Journal:  Andrology       Date:  2016-03-16       Impact factor: 3.842

7.  Genetic analysis of strains C57BL/6J and BALB/cJ for Ath-1, a gene determining atherosclerosis susceptibility in mice.

Authors:  B Paigen; D Mitchell; P A Holmes; D Albee
Journal:  Biochem Genet       Date:  1987-12       Impact factor: 1.890

8.  Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters.

Authors:  A Gambineri; C Pelusi; R Pasquali
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

9.  Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels.

Authors:  T Soygür; B Küpeli; K Aydos; S Küpeli; N Arikan; Y Z Müftüoğlu
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

10.  MLL histone methylases regulate expression of HDLR-SR-B1 in presence of estrogen and control plasma cholesterol in vivo.

Authors:  Khairul I Ansari; Sahba Kasiri; Imran Hussain; Samara A Morris Bobzean; Linda I Perrotti; Subhrangsu S Mandal
Journal:  Mol Endocrinol       Date:  2012-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.